Source: Annual Congress 2001 - Pulmonary hypertension: what's new?
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Morales, J. A. Barbera, E. Gavela, E. Sala, F. Burgos, A. Torres, M. Melgosa, S. Santos, J. Roca, R. Rodriguez-Roisin (Barcelona, Palma de Mallorca, Spain). The vasodilator response to inhaled nitric oxide (iNO) predicts the short term evolution with oral vasodilators in pulmonary arterial hypertension. Eur Respir J 2001; 16: Suppl. 31, 131

Member's Comments

No comment yet.

Related content which might interest you: The acute haemodynamic effects of 'pulsed' inhaled nitric oxide and iv epoprostenol in patients with pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 584s Year: 2003 The effect of inhaled nitric oxide on the cardiac performance in patients with hypoxic pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 269s Year: 2003 Comparison of hemodynamic effects of inhaled nitric oxide (iNO) and inhaled epoprostenol (iEPO) in patients with pulmonary hypertension (PH) Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 Tolerance of long term nitric oxide treatment in severe arterial pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 370s Year: 2002 Comparative effects of inhaled nitric oxide and aerosolized iloprost during vasoreactivity testing in chronic pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 561s Year: 2005 Haemodynamic testing in primary pulmonary hypertension - effects of nitric oxide, iloprost and oxygen Source: Eur Respir J 2001; 18: Suppl. 33, 414s Year: 2001 Inhaled nitric oxide (NO) for vasoreactivity testing in pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 584s Year: 2003 Influence of inhaled nitric oxide on plasma endothelin-1 in pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 463s Year: 2003 Vasoreactivity to inhaled nitric oxide does not predict long term survival in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016 Feasibility of home treatment with inhaled nitric oxide for primary pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 598s Year: 2002 Correlation of inhaled nitric-oxide induced reduction of pulmonary artery pressure and vascular changes Source: Eur Respir J 2002; 20: 52-58 Year: 2002 Sildenafil enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 24s Year: 2002 Effect of the Asp298 variant of endothelial nitric oxide synthase on acute pulmonary vasodilator testing response in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 547s Year: 2006 Acute vasoresponsiveness to inhaled nitric oxide in sarcoidosis-associated pulmonary hypertension Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008 Endogenous endothelins and nitric oxide in hypoxic pulmonary vasoconstriction Source: Eur Respir J 2003; 21: 19-24 Year: 2003 Bronchial nitric oxide output predicts responsiveness to inhaled steroids in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 429s Year: 2004 Nitric oxide vs prostacyclin in chronic high-flow pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 24s Year: 2002 Combination of inhaled nitric oxide and an endothelinA-receptor antagonist in acute pulmonary thromboembolism Source: Eur Respir J 2003; 22: Suppl. 45, 463s Year: 2003 Nitric oxide metabolite flux during exercise in pulmonary arterial hypertension Source: Annual Congress 2011 - Physiology of human pulmonary hypertension Year: 2011 Endothelin system, exhaled nitric oxide and high altitude pulmonary hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 551s Year: 2007